Tirzepatide
Also called: Mounjaro, Zepbound
Tirzepatide is a synthetic peptide that activates two gut-hormone receptors at once: GLP-1 and GIP. It is made by Eli Lilly and sold in the UK as Mounjaro for both type 2 diabetes and weight management. The dual mechanism produces stronger weight-loss results than semaglutide in clinical trials, with side effects of similar character.
What makes it different
Most GLP-1 drugs target just the GLP-1 receptor. Tirzepatide is the first approved drug to target both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone, also released by the gut after eating. The combination produces stronger insulin release and more weight loss than either signal alone, at least in current trials. Drugs that target three receptors at once (like retatrutide, in late-stage trials) are next.
How weight loss compares to semaglutide
In the SURMOUNT-1 trial of tirzepatide for obesity, participants on the highest dose (15 mg weekly) lost an average of 22.5 percent of body weight over 72 weeks. The same trial design with semaglutide (STEP-1) showed 14.9 percent. Real-world results vary, and the SURPASS trials in diabetes showed slightly smaller differences. NICE approved tirzepatide for obesity in the UK in 2024 (TA1026), with eligibility limited to BMI 35 or above with weight-related conditions, plus structured behavioural support.
Doses and titration
- Starting dose: 2.5 mg once weekly, for 4 weeks.
- Step 2: 5 mg weekly. Many people stay here.
- Higher doses: 7.5 mg, 10 mg, 12.5 mg, 15 mg. Titrated up at 4-week intervals if tolerated and required.
- Each dose step typically triggers a 1 to 2 week recurrence of side effects before the gut adapts.
Side effects
The side-effect profile is similar to semaglutide. Nausea is the most common, affecting around 30 to 40 percent of users at higher doses. Constipation hits roughly 1 in 6 users on average across the SURMOUNT trials, rising to closer to 1 in 5 at the highest 15 mg dose. Sulphur burps are reported more often by tirzepatide users than semaglutide users in real-world reporting. Most symptoms peak in weeks 2 to 4 of each dose escalation and ease as the gut adapts.
How it is taken in the UK
Mounjaro is prescription-only. It is available privately through online and high-street pharmacies, and via the NHS for diabetes. NHS access for obesity is being phased in from 2025, starting with patients with BMI 40 or above with four weight-related comorbidities. Private prices in the UK ranged from around £150 to £260 per month in 2026, depending on dose and pharmacy.
Common questions
- Is Mounjaro stronger than Ozempic?
- On weight loss, yes. The SURMOUNT-1 trial of tirzepatide produced 22.5 percent average weight loss at the highest dose, compared with 14.9 percent for semaglutide in STEP-1. Side effects are similar in frequency and character.
- What is the difference between Mounjaro and Zepbound?
- Both contain tirzepatide and are made by Eli Lilly. Mounjaro is the brand used in the UK and EU for both diabetes and obesity. Zepbound is the brand used in the United States for obesity only. The drug is identical.
- How long do you stay on tirzepatide?
- Clinical guidance treats GLP-1 receptor agonists as long-term therapy in most cases, similar to medications for blood pressure or cholesterol. NICE TA1026 funds tirzepatide for obesity in the NHS for an initial two years with review. Stopping leads to weight regain in around two thirds of patients within a year unless eating habits, exercise and lean mass have been protected.
- Why do tirzepatide users get sulphur burps?
- Slowed gastric emptying means food and stomach contents sit longer than normal. Some of the sulphur-containing amino acids and bile acids volatilise, producing the characteristic egg-like smell. The simplest fix is smaller meals, slower eating, and giving the gut time to clear before sleeping.